Liver-Expressed Chemokine/CC Chemokine Ligand 16 Attracts Eosinophils by Interacting with Histamine H4 Receptor

Takashi Nakayama, Yoshiko Kato, Kunio Hieshima, Daisuke Nagakubo, Yuichi Kunori, Takao Fujisawa and Osamu Yoshie

*J Immunol* 2004; 173:2078-2083; doi: 10.4049/jimmunol.173.3.2078
http://www.jimmunol.org/content/173/3/2078

**References**
This article cites **28 articles**, 17 of which you can access for free at:
http://www.jimmunol.org/content/173/3/2078.full#ref-list-1

**Subscription**
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Liver-Expressed Chemokine/CC Chemokine Ligand 16 Attracts Eosinophils by Interacting with Histamine H4 Receptor

Takashi Nakayama,* Yoshiko Kato,† Kunio Hieshima,* Daisuke Nagakubo,* Yuichi Kunori,† Takao Fujisawa,‡ and Osamu Yoshie*‡§

Liver-expressed chemokine (LEC)/CCL16 is a human CC chemokine that is constitutively expressed by the liver parenchymal cells and present in the normal plasma at high concentrations. Previous studies have shown that CCL16 is a low-affinity ligand for CCR1, CCR2, CCR5, and CCR8 and attracts monocytes and T cells. Recently, a novel histamine receptor termed type 4 (H4) has been identified and shown to be selectively expressed by eosinophils and mast cells. In this study, we demonstrated that CCL16 induced pertussis toxin-sensitive calcium mobilization and chemotaxis in murine L1.2 cells expressing H4 but not those expressing histamine receptor type 1 (H1) or type 2 (H2). CCL16 bound to H4 with a $K_d$ of 17 nM. By RT-PCR, human and mouse eosinophils express H4 but not H3. Accordingly, CCL16 induced efficient migratory responses in human and mouse eosinophils. Furthermore, the responses of human and mouse eosinophils to CCL16 were effectively suppressed by thioperamide, an antagonist for H3 and H4. Intravenous injection of CCL16 into mice induced a rapid mobilization of eosinophils from bone marrow to peripheral blood, which was also suppressed by thioperamide. Collectively, CCL16 is a novel functional ligand for H4 and may have a role in trafficking of eosinophils. The Journal of Immunology, 2004, 173: 2078–2083.

Chemokines play important roles in innate and acquired immunity by inducing directed migration of various types of leukocytes through interactions with a group of seven-transmembrane G protein-coupled receptors (GPCRs)1 (1). Liver-expressed chemokine (LEC)/CCL16 (2), also known as novel CC chemokine 4 (2), human CC chemokine 4 (3), lymphocyte and monocyte chemoattractant (4), and liver-specific CC chemokine 1 (5), is selectively expressed in the liver and present in the normal plasma at high concentrations (6). CCL16 was shown to be induced in monocytes by IL-10 (3) and chemotactic for monocytes and lymphocytes (3, 4). In addition, this chemokine was shown to have a potent myelosuppressive activity comparable to that of MIP-1α/CCL3 (4) and to induce tumor rejection (7). Previously, we have shown that CCL16 is a low-affinity functional ligand for CCR1, CCR2, and CCR5 (6). Separately, Howard et al. (8) reported that CCL16 induced chemotaxis and cell adhesion to matrix proteins of human monocytes via CCR1 and CCR8. However, its physiological role still remains mostly unknown.

Histamine receptor type 4 (H4) is the most recently identified subtype of histamine receptors (9, 10). H4 is selectively expressed by cells such as eosinophils and mast cells and mediates histamine-induced chemotaxis and calcium mobilization in these types of cells (11, 12). Chemoattractant receptors including those for chemokines often interact with quite diverse molecules. For example, CCR6, the receptor for CCL20 (1), is also a receptor for β-defensins (13). HIV-1 Tat protein attracts monocytes via CCR2 and CCR3 (14). Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, the autoantigens in myositis, attract T cells, IL-2-activated monocytes, and immature dendritic cells via CCR5 and CCR3, respectively (15). Formyl peptide receptor-like-1, the low-affinity receptor for the bacterial chemotactic peptide fMLF, is also a receptor for lipoxin A4 and acute phase protein serum amyloid A (16, 17). Given such versatility in the chemoattractant receptors in terms of ligand-specificity, we tested a large panel of human chemokines on histamine receptors H1, H2, and H4 (18). In this study, we report that CCL16 is a functional ligand for H4 and induces an efficient migration of human and mouse eosinophils via H4.

Materials and Methods

Materials

All recombinant human chemokines were purchased from R&D Systems ( Minneapolis, MN). Histamine and thioperamide were purchased from Sigma-Aldrich ( St. Louis, MO). Pertussis toxin (PTX) was purchased from Invitrogen ( Carlsbad, CA). A murine L1.2 pre-B cell line was kindly provided by E. Butcher ( Stanford University School of Medicine, Stanford, CA).

Stable expression of histamine receptors

The coding regions of human histamine receptors H1, H2, and H4 were amplified from a cDNA library generated from PHA-stimulated PBMC by PCR. The cDNAs were cloned into a retroviral vector pMX-IRES/EGFP (19) and recombinant retroviruses were obtained. L1.2 cells were infected with the recombinant viruses and stable transfectants expressing green fluorescence were selected by FACS.
Calcium mobilization assay
Cells were suspended at 10^6 cells/ml in HBSS containing 1 mg/ml BSA and 10 mM HEPES (pH 7.4), and loaded with 3 mM Fluo-2-AM fluorescent dye (Molecular Probes, Eugene, OR). After washing, cells were placed in F2000 fluorescence spectrophotometer (Hitachi, Tokyo, Japan) and stimulated with recombinant human chemokines or histamine. Emission fluorescence at 510 nm was measured upon excitation at 340 and 380 nm to obtain the fluorescence intensity ratio (R340/380).

Chemotaxis assay
This was conducted using Transwell plates with 5-μm pore polycarbonate membrane filters (Costar, Acton, MA) as described previously (20). Migrated cells were quantitated using PicoGreen dsDNA quantitation reagent (Molecular Probes) (20).

Binding assay
Recombinant human CCL16 was radiolabeled to a specific activity of 1-2 × 10^6 cpm/μg by using [125I]-labeled Bolton and Hunter reagents (Amersham Biosciences, Piscataway, NJ). For binding experiments, 1 ml of 0.25% bupivacaine (Sigma-Aldrich) using a disposable insulin syringe. At 3 and 10 days, mice were injected with 75 μg of CCL16 expression plasmid into the soleus muscles with 50 μl of PBS into bupivacaine-injected sites. After 2–3 wk, splenic eosinophils were purified from mice that had >50% eosinophils in the blood. spleen cells were layered onto a Ficoll-Paque PLUS gradient (30% and 40% Ficoll-Paque PLUS) and were centrifuged at 250 g for 20 min. Eosinophils were layered between 1.07 and 1.09 g/ml. Eosinophils were further purified by two times negative selection using anti-CD90 (Thy1.2), anti-CD45R (B220), and anti-CD8α (Ly-2)-bound micromagnetic beads and IMagnet (BD Biosciences).

After negative selections, the purity of eosinophils was consistently >90%, and their viability was consistently >95%.

Eosinophil mobilization in mice
Female BALB/c mice, 6 wk old, were purchased from CLEA and kept in specific pathogen-free conditions for at least 1 wk before experiments. Mice were injected i.v. with 100 μl of PBS without or with 0.5 nmol of CCL16. At various time points, mice were given anesthesia by inhalation of diethyl ether and peripheral blood was collected. After blood collection, mice were sacrificed by cervical dislocation and femurs were obtained. The ends of femurs were removed and bone marrow cells were recovered by flushing with 1 ml of PBS. Smears were stained with May-Grünwald and Giemsa solutions. Differential cell counts were performed for at least 500 cells/slide. All animal experiments were performed in accordance with the guidelines of the Center of Animal Experiments, Kinki University School of Medicine.

Results
CCL16 induces calcium mobilization via H4
Histamine receptors H1, H2, and H4 are variably expressed by hemopoietic cells, while H3 is selectively expressed by neurons in the CNS (10–12, 18). To examine whether any chemokines act as an agonist for the histamine receptors, we performed calcium mobilization assays using murine L1.2 pre-B cells stably expressing H1, H2, or H4 (L1.2-H1, L1.2-H2, and L1.2-H4, respectively). Among 32 recombinant human chemokines tested at 100 nM (CC chemokines: CCL1, 2, 3, 4, 5, 7, 8, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 24, 25, 26, 27, and 28; CX chemokines: CXCL4, 8, 9, 10, 12, 13, and 16; CCL1; CX3CL1), CCL16 was found to induce vigorous calcium mobilization in L1.2-H4. Fig. 1A shows that, while histamine induced calcium mobilization via H1 and H4, CCL16 dose-dependently induced calcium mobilization via H4 but not via H1 or H2. Furthermore, H4-mediated calcium mobilization induced by CCL16 was completely suppressed by PTX, supporting that H4 couples with the Gα class of G proteins (9, 10). Fig. 1B shows that CCL16 dose-dependently desensitized histamine-induced calcium mobilization via H4. Conversely, histamine desensitized CCL16-induced calcium mobilization via H4. Furthermore, thioperamide, an antagonist for H3 and H4 (10, 22), completely suppressed CCL16- and histamine-induced calcium mobilization via H4. Collectively, CCL16 is a novel agonist for H4.

CCL16 induces chemotactic responses via H4
We next examined chemotactic responses of L1.2-H1, L1.2-H2, and L1.2-H4 to CCL16. As shown in Fig. 2A, both CCL16 and histamine induced vigorous cell migration in L1.2-H4 with a typical bell-shaped dose-response curve. In contrast, neither CCL16 nor histamine induced any significant migration in L1.2-H1 or L1.2-H2. Thus, these histamine receptors are not coupled with the Gαi class of G proteins in L1.2 cells. As shown in Fig. 2B, thioperamide, an antagonist for H3 and H4 (10, 22), dose-dependently suppressed migratory responses of L1.2-H4 to 100 nM CCL16 with an IC_{50} of 50 μM. As shown in Fig. 2C, CCL16 and histamine were additive in inducing migration of L1.2-H4 cells. As shown in Fig. 2D, a checkerboard-type analysis confirmed that CCL16 induced mostly chemotaxis, not chemokinesis, in L1.2-H4. As shown in Fig. 2E, PTX, the inhibitor of the Gαi class of G proteins, suppressed CCL16-induced migratory responses of L1.2-H4.

Specific binding of CCL16 to H4
We next examined binding of CCL16 to H4. As shown in Fig. 3A, [125I]-labeled CCL16 specifically bound to L1.2-H4. Scatchard analysis revealed a single class of binding sites with a K_d of 17 nM and 41,000 sites/cell (Fig. 3B). Furthermore, binding of [125I]-labeled CCL16 at 10 nM was completely inhibited by unlabeled CCL16, histamine, and thioperamide with an IC_{50} of 8.8, 4.1, and 57 nM, respectively (Fig. 3C).
Eosinophil responses to CCL16

H4 is selectively expressed by eosinophils and mediates eosinophil migration to histamine (10, 11). By RT-PCR, we confirmed that human and mouse eosinophils expressed H4 but not H3 (Fig. 4A).

We, therefore, examined induction of eosinophil migratory responses by CCL16. As shown in Fig. 4B (left), CCL16 dose-dependently induced a highly efficient migration of human eosinophils. In fact, many more eosinophils migrated to CCL16 at 100 or 1000 nM than to eotaxin/CCL11 at its optimal concentration of 10 nM. CCL16 also induced less efficient but still vigorous migration in mouse eosinophils (Fig. 4B, right). Furthermore, thioperamide, an antagonist for H3 and H4 (10, 22), dose-dependently suppressed migratory responses of human and mouse eosinophils to CCL16 (Fig. 4C). Fig. 4D further shows induction of calcium mobilization in mouse eosinophils by CCL16 and histamine as well as their mutual desensitization. Again, thioperamide completely suppressed CCL16-induced calcium mobilization in mouse eosinophils.

**FIGURE 1.** Induction of calcium mobilization in H4-expressing L1.2 cells by CCL16. A, H4-specific calcium mobilization by CCL16. L1.2 cells stably expressing H1 (L1.2-H1), H2 (L1.2-H2), or H4 (L1.2-H4) were loaded with Fura 2-AM. Cells (5 × 10^5/assay) were stimulated with CCL16 or histamine at indicated concentrations. Intracellular calcium mobilization was measured on a fluorescence spectrophotometer. Pretreatment of L1.2-H4 cells with PTX at 500 ng/ml was performed at 37°C for 30 min. Representative results from three separate experiments are shown. B, Mutual desensitzation of CCL16 and histamine in calcium mobilization via H4. L1.2-H4 cells were loaded with Fura 2-AM and stimulated with CCL16 or histamine as indicated. Intracellular calcium mobilization was measured on a fluorescence spectrophotometer. Thioperamide was used at 50 μM. Representative results from three separate experiments are shown.

**FIGURE 2.** Induction of chemotaxis in H4-expressing L1.2 cells by CCL16. A, Dose-response experiments. Chemotactic responses of L1.2 cells stably expressing H1 (L1.2-H1), H2 (L1.2-H2), and H4 (L1.2-H4) to indicated concentrations of histamine and CCL16 were examined. B, Inhibition of CCL16-induced migration of L1.2-H4 cells by thioperamide. Chemotactic responses of L1.2-H4 cells to CCL16 at 100 nM were determined in the presence of indicated concentrations of thioperamide. C, Additive effects of histamine and CCL16. Chemotactic responses of L1.2-H4 cells to indicated concentrations of CCL16 without (□) or with 10 nM of histamine (■) were determined. D, A checkerboard-type analysis. In chemotactic assays using L1.2-H4 cells, CCL16 was added to upper and/or lower wells at 100 nM as indicated. E, Inhibition by PTX. L1.2-H4 cells were pretreated at 37°C for 30 min without or with PTX at 500 ng/ml and examined for chemotactic responses to CCL16 at 100 nM. All assays were done in duplicate and numbers of cells migrated to lower wells were expressed by percent input cells. Results are shown as mean ± SEM from three separate experiments.

**Eosinophil responses to CCL16**

Expression of H4 was consistently seen in the human, rat, mouse, and guinea pig bone marrow (Fig. 4A) (10, 22). Since CCL16 is selectively expressed in the liver and present in the normal plasma...
Histamine is an important biogenic amine and one of the major products of mast cells. Histamine exerts diverse physiological functions via four subtypes of histamine receptors, namely, H1, H2, H3, and H4, which are all GPCRs (18). These receptors are differentially expressed in various types of cells and mediate diverse functions via four subtypes of histamine receptors, namely, H1, H2, and H3, which are all GPCRs (18). Notably, H1, H2, and H3 share less protein sequence identity with each other than with other biogenic amine receptor family members, suggesting that they may have evolved from different ancestral genes (Fig. 6). H4 is the most recently identified subtype of histamine receptor with an amino acid identity of ~38% to H3 (9, 10). H4 has been shown to be primarily expressed by eosinophils and responsible for histamine-induced migration of eosinophils (10, 11). In the present study, we have demonstrated that CCL16, which is a low-affinity ligand for CCR1, CCR2, CCR5, and CCR8 (6, 8), is also a novel agonist for H4. CCL16 induced vigorous calcium mobilization and chemotaxis through H4 (Figs. 1 and 2) and specifically bound to H4 with a $K_d$ of 17 nM (Fig. 3). At the molar basis, CCL16 and histamine are almost equivalent in potency as an agonist for H4 (Figs. 2 and 3). Fig. 6 shows the phylogenetic relationships of the chemokine receptors (for the sake of simplicity, only four members are
shown) and the histamine receptors. Chemokine receptors are closely related to GPCRs for peptide ligands, while histamine receptors H1 and H2 are the members of GPCRs for biogenic amines. However, H3 and H4, which are most closely related to each other, are only remotely related to other biogenic amine receptors including H1 and H2 and have a closer phylogenic relationship with GPCRs for peptide ligands than other biogenic amine receptors. At any rate, this is the first time of a demonstration of an interaction of a chemokine with a GPCR quite different from the chemokine receptors. Given the versatility of the GPCR system, however, such unexpected interactions may be more frequent than anticipated.

In consistence with the selective expression of H4 in eosinophils (Fig. 4A) (10, 11), CCL16 induced vigorous migration in human and mouse eosinophils in vitro (Fig. 4) and rapid mobilization of bone marrow eosinophils into peripheral blood in mice (Fig. 5). Furthermore, thioperamide, an antagonist for H3 and H4 (10, 22), effectively suppressed all of those responses of eosinophils to CCL16 (Figs. 4 and 5). H3 is known to be selectively expressed in the CNS and primarily by neurons (18). By using RT-PCR, we confirmed that human and mouse eosinophils express H4 but not H3 (Fig. 4A). Furthermore, human eosinophils do not express CCR1, CCR2, CCR5, or CCR8 (23). Thus, it can be safely concluded that H4 mediates eosinophil responses to CCL16. Since CCL16 is constitutively expressed by the liver parenchymal cells and present in the normal plasma at relatively high concentrations (average, 50 ng/ml) (6), CCL16 may have a role in mobilization of eosinophils from the bone marrow (Fig. 5). In addition, CCL16 is known to be induced in monocytes by IL-10 (3). Therefore, CCL16 may be produced by monocytes and tissue macrophages in Th2-dominant inflammatory conditions and attract eosinophils into inflammatory sites. Furthermore, CCL16 and histamine, whose effects on H4 are additive (Fig. 2), may cooperatively promote eosinophil migration in allergic conditions. CCL16 may also play a significant role in certain liver diseases such as drug-induced liver damages that are known to be associated with liver infiltration of eosinophils and/or blood eosinophilia (24–27). Furthermore, CCL16 may also play a role in migration of other hemopoietic cells such as dendritic cells and mast cells that also express H4 (12, 28). Even though CCL16 is effective only at relatively high concentrations, the versatility of CCL16 as a ligand for CCR1, CCR2, CCR5, CCR8, and even H4 may allow it to have a substantial role in trafficking of various types of hemopoietic cells. These possibilities remain to be seen.

Acknowledgments

We thank Namie Sakiyama for excellent technical assistance.
References


